Yearly STL Archives: 2025
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.
Nanodermatology
Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.
Update on Drugs & Devices: July-August 2025
Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™).
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.
A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne
IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.
Update on Drugs & Devices: May-June 2025
Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®).
Roflumilast for the Treatment of Seborrheic Dermatitis: A Review
Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.
Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab’s Efficacy and Utilization
Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.
Update on Drugs & Devices: March-April 2025
Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™).
Pediatric Hidradenitis Suppurativa: An Overview
Explore a comprehensive overview of pediatric hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This article delves into its epidemiology, pathogenesis, clinical features, associated comorbidities, and treatment challenges. Gain insights into the unique aspects of pediatric HS, including its impact on quality of life and the importance of early diagnosis and management.
An Update on the Clinical Management of Cutaneous Leishmaniasis
Discover the latest insights into managing cutaneous leishmaniasis (CL), including its epidemiology, prevention, diagnosis, and treatment advancements. This article highlights rising global cases, travel-related risks, and evolving clinical strategies to combat this neglected tropical disease.
Update on Drugs & Devices: January-February 2025
Update on Cosibelimab-ipdl IV use (Unloxcyt™), Ustekinumab-kfce SC/IV use (Yesintek™), Minocycline hydrochloride capsules (Emrosi™).
